Key result
Simulated ceftaroline every eight hours maintains ~90% target attainment in adults with cystic fibrosis.
Why the study?
The pharmacokinetics and pharmacodynamics of ceftaroline in adults with cystic fibrosis were not well characterized, necessitating evaluation to guide dosing.
What are the pharmacokinetics and pharmacodynamics of ceftaroline in adults with cystic fibrosis?
What are the pharmacokinetics and pharmacodynamics of ceftaroline in adults with cystic fibrosis?
The pharmacokinetics of ceftaroline are altered in adults with cystic fibrosis, requiring a modified dosage of 600 mg every 8 hours to achieve adequate pharmacodynamic targets.
Suggests adjusted dosing may be needed in cystic fibrosis; hypothesis-generating and requires prospective validation before practice change.
No takes yet. Share an insight, caveat, or question.
Autry et al. (2016) studied Cystic fibrosis (n=8). Ceftaroline was evaluated on Probability of target attainment (PTA) for 60% or higher of the dosing interval during which free drug concentrations exceed the minimum inhibitory concentration (%fT > MIC). In adults with cystic fibrosis, Monte Carlo simulations showed that intravenous ceftaroline 600 mg every 8 hours maintained a >90% probability of target attainment for 60% fT > MIC.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: